Ivax/Nycomed merger off: replaced by marketing alliance in U.S. and Europe.
Executive Summary
IVAX TO MARKET NYCOMED's NSAID LORNOXICAM: MERGER AGREEMENT OFF, the companies announced Nov. 15. Hafslund Nycomed will license North American rights to its non-steroidal anti-inflammatory agent for moderately severe pain to Ivax as part of a broad marketing alliance between the two firms. An NDA for lornoxicam has been filed, according to Nycomed materials distributed at a recent Oppenheimer & Co. conference in New York City. Ivax will also gain rights to Nycomed's hybrid toxin to treat brain tumors.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth